Physician profile
Paul E Meyer
NPI 1134174865
$2,619.09
in general payments reported to CMS, 2019-2025
12 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $92.27 · 2021: $192 · 2022: $112 · 2023: $215 · 2024: $1,607 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,050 · Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,050.00 |
| Food and Beverage | $921.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,050.00 | 2024 | Imfinzi |
| Atricure, INC. | $446.46 | 2022-2025 | Atriclip Laa Exclusion System |
| Edwards Lifesciences Corporation | $244.59 | 2019-2025 | Sapien 3 Ultra Resilia |
| American Orthodontics Corporation | $168.75 | 2020-2021 | |
| Becton, Dickinson and Company | $165.00 | 2024 | Progel Applicator Spray Tips |
| Abbott Laboratories | $152.70 | 2023 | Navitor |
| Medtronic, INC. | $129.98 | 2021-2024 | Corevalve Evolut R |
| Boston Scientific Corporation | $126.21 | 2019-2025 | General - Thrombectomy |
| Davol INC. | $68.77 | 2019 | |
| Abiomed | $36.70 | 2022 | |
| Bard Peripheral Vascular, INC. | $18.00 | 2024 | Rotarexs 6 F X 135 Cm |
| Medtronic Vascular, INC. | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.